Physician profile
Abbe Miller
NPI 1215933973
$3,704.15
in general payments reported to CMS, 2019-2025
21 companies · $554 in 2025
The $554 reported for 2025 was more than what 80% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $479 · 2020: $371 · 2021: $884 · 2022: $677 · 2023: $430 · 2024: $310 · 2025: $554.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,294.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,293.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $748.15 | 2019-2025 | |
| Kaleo, INC. | $464.31 | 2019-2024 | Auvi-Q |
| Genentech USA, INC. | $453.50 | 2019-2025 | Xolair |
| Optinose US, INC. | $343.68 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $315.27 | 2019-2025 | Fasenra, Tezspire |
| Regeneron Healthcare Solutions, INC. | $290.66 | 2021-2025 | Dupixent |
| Glaxosmithkline, LLC. | $242.48 | 2019-2025 | Trelegy Ellipta, Arexvy |
| Pfizer INC. | $132.07 | 2019-2025 | |
| Globus Medical, INC. | $125.00 | 2022 | |
| Csl Behring | $100.16 | 2019-2025 | Andembry |
| Abbvie INC. | $90.45 | 2022-2023 | |
| Ars Pharmaceuticals Operations, INC. | $86.21 | 2025 | Neffy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $69.37 | 2020-2021 | |
| Leo Pharma INC. | $65.04 | 2022-2023 | Adbry |
| Biocryst US Sales Co., LLC | $57.75 | 2023-2024 | Orladeyo |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $31.63 | 2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $22.47 | 2025 | Eohilia |
| Alk-Abello, INC | $20.20 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $15.46 | 2021 | |
| Amgen INC. | $15.17 | 2022 | |
| Biocryst Pharmaceuticals, INC. | $15.12 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Abbe Miller listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.